Historique
Rapport
WHO expert committee on drug dependence. Critical review: CUMYL-4CN-BINACA
Accompagne :
Auteur(s) :
OMS / WHO (Organisation mondiale de la santé / World Health Organization) ;
Expert Committee on Drug Dependence, Forty-first Meeting (12-16 November 2018; Geneva, Switzerland)
Année
2018
Page(s) :
19 p.
Sous-type de document :
Revue de la littérature
Langue(s) :
Anglais
Éditeur(s) :
Genève : OMS / WHO
Collection :
Rapports techniques / Technical report series
Domaine :
Drogues illicites
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus géographique
INTERNATIONAL
Thésaurus mots-clés
CANNABINOIDES
;
PHARMACOLOGIE
;
CHIMIE
;
LEGISLATION
;
EPIDEMIOLOGIE
;
PREVALENCE
;
TOXICOLOGIE
;
DROGUES DE SYNTHESE
;
FABRICATION
;
CONTROLE DES STUPEFIANTS
Note générale :
This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence.
Résumé :
Substance identification: CUMYL-4CN-BINACA (CAS: 1631074-54-8) is a synthetic cannabinoid that was first documented in international patent WO 2014/167530-Al issued to Matthew Bowden and James Williamson on October 16, 2014.
WHO Review History: The WHO has not previously reviewed CUMYL-4CN-BINACA.
Chemistry: CUMYL-4CN-BINACA is 1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide. It does not have any stereoisomers.
Ease of convertibility into controlled substances: CUMYL-4CN-BINACA is not readily converted into other controlled substances.
Similarity to known substances / Effects on the central nervous system: CUMYL-4CN-BINACA is a synthetic cannabinoid that likely shares a profile of centrally mediated effects with other synthetic cannabinoids, including THC-like intoxication. Examination of the in vivo effects of this compound specifically is limited. [Extract from the executive summary]
WHO Review History: The WHO has not previously reviewed CUMYL-4CN-BINACA.
Chemistry: CUMYL-4CN-BINACA is 1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide. It does not have any stereoisomers.
Ease of convertibility into controlled substances: CUMYL-4CN-BINACA is not readily converted into other controlled substances.
Similarity to known substances / Effects on the central nervous system: CUMYL-4CN-BINACA is a synthetic cannabinoid that likely shares a profile of centrally mediated effects with other synthetic cannabinoids, including THC-like intoxication. Examination of the in vivo effects of this compound specifically is limited. [Extract from the executive summary]